4DMedical Expands Lung Imaging Technology with Integral Diagnostics Contract

4DMedical Ltd ( (AU:4DX) ) has shared an announcement.

4DMedical Limited has successfully transitioned its pilot program with Integral Diagnostics into a commercial contract, marking a significant expansion of its lung imaging technology across Victoria, Australia. This development will enhance access to 4DMedical’s advanced diagnostic tools for general practitioners, respiratory specialists, and cardiologists, improving patient outcomes through more accurate and timely diagnoses of respiratory conditions. The contract signifies strong demand for 4DMedical’s innovative solutions and reinforces its commitment to revolutionizing lung health, further solidifying its commercial presence in the Australian market.

More about 4DMedical Ltd

4DMedical Limited (ASX:4DX) is a global leader in medical technology, specializing in advanced respiratory imaging solutions. The company leverages cutting-edge imaging and AI-powered technologies to provide detailed insights into lung function, facilitating early and accurate diagnosis of respiratory diseases. Their patented XV Technology® and FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) offer unprecedented sensitivity in detecting and monitoring lung abnormalities. 4DMedical’s solutions are designed to integrate seamlessly into existing hospital systems through a Software as a Service (SaaS) model, enhancing diagnostic capabilities and supporting personalized patient care.

YTD Price Performance: -46.88%

Average Trading Volume: 995,622

Technical Sentiment Signal: Buy

Current Market Cap: A$114.9M

For detailed information about 4DX stock, go to TipRanks’ Stock Analysis page.